ERBB2 and breast carcinoma: Taken together, we demonstrate that by destabilizing ERBB2, we controlled and downregulated YES1 and WNK1 that are well-known causes of drug resistance in ERBB2+ trastuzumab drug-resistant breast cancer and in osimertinib-resistant EGFR T790M lung cancer, respectively (Kute et al 2004; Zazo et al 2016; Wang et al 2020; Jaykumar et al., 2021).